Far-IR Emitted by Compression Stockings for Cellulitis Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01429428|
Recruitment Status : Unknown
Verified September 2011 by Edileia Bagatin, Federal University of São Paulo.
Recruitment status was: Active, not recruiting
First Posted : September 7, 2011
Last Update Posted : September 7, 2011
This is a randomized and controlled study to investigate if the far-IR radiation emitted by compression stockings fabric may be effective and safe as adjuvant treatment for cellulitis that affects the majority of women after puberty.
The investigators expect that the far-IR effects on superficial microcirculation,deep dermis and subcutaneous fat may attenuate the clinical aspect of cellulitis.
|Condition or disease||Intervention/treatment||Phase|
|Cellulitis Quality of Life||Other: Far-IR compression stockings Other: No far-IR compression stockings||Not Applicable|
Cellulitis is a sex-specific, anatomic and normal condition affecting women after puberty.The main clinical aspect is the irregularity on skin surface which is classified in 4 grades, 0 to III, according to Nurenberg classification, 1978.
It is a multifactorial condition, involving: herniation of subcutaneous fat into deep dermis; vertical fibrous septum from fatty tissue to dermis; alterations in microcirculation; hormonal and inflammatory factors Clinical evaluation is very difficult and the best methods are: high resolution ultrasound and magnetic resonance.
There is no effective management. Many devices have been introduced to treat that aesthetic condition which causes a great discomfort to women. There are few controlled studies with high level methodology and consistent conclusions.
The far-IR radiation can be obtained by low energy emitting devices and its main effects are the interaction with water and temperature increase. This method had already shown efficacy for circulation system disorders and wound healing by activation of TGF-beta and fibroblasts.
Our aim is to evaluate the benefits of far-IR for cellulitis control.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Randomized and Controlled Study About Efficacy and Safety of Far-Infra Red Radiation Emitted by Compression Stockings for Cellulitis Treatment|
|Study Start Date :||July 2011|
|Estimated Primary Completion Date :||November 2011|
|Estimated Study Completion Date :||March 2012|
Placebo Comparator: Stockings side one
This side of the compression stockings is just the fabric (placebo).
Other: No far-IR compression stockings
This side of compression stocking without far-IR radiation will be used by subjects, during the day, for six hours a day, during 90 days.
Active Comparator: Stocking side two
This side of compression stocking emits far-IR radiation.
Other: Far-IR compression stockings
The far-IR side of compression stocking will be used by subjects, during the day, for six hours a day, during 90 days.
- Changes in ultra-sound images [ Time Frame: 0, 30, 60 and 90 days ]High resolution ultra-sound (DemaScan, Cortex Technology, Denmark)is used to measure dermis density and thickness and distance between dermis and fatty tissue in the most evident two areas with cellulitis(thighs and buttocks)
- Changes in Cellulitis clinical grade [ Time Frame: 0, 30, 60 and 90 days ]
Main investigator evaluates the clinical aspect of cellulitis, i.e., the level of irregularity of skin surface, according to Nuremberg and Müller classification in four grades:
0: no alterations I: alterations only visible by pinching the skin or contracting the muscles II: skin orange or padded aspect is visible when the woman stands up or by pinching the skin or contracting the muscles III: the same alterations of II associated to skin elevations and nodulations
- Subject evaluation [ Time Frame: day 90th ]Study subjects will give their opinion about modification on cellulitis appearance using a 5-point scale: much worse; worse; no change; better; much better
- Changes in Anthropometric measures [ Time Frame: 0, 30, 60 and 90 days ]The circumference of thighs, hip and waist are measured in standardized points
- Changes in Photographies [ Time Frame: 0, 30, 60 and 90 days ]By using the OMNIA device standardized photos are taken in three positions: front buttocks and side view of thighs
- Changes in Skin viscoelasticity [ Time Frame: 0, 30, 60 and 90 days ]Skin elasticity is measured by suction with the Cutometer device(Courage&Khazaka, Germany) in the most evident two areas with cellulitis(thighs and buttocks)
- Changes in DLQI scores [ Time Frame: 0 and 90 days ]The application of the quality of life generic questionnaire named Dermatology Life Quality Index or DLQI(Finlay, 1994), version DLQI-Brasil (Ferraz, 2006) will be used to evaluate the impact of cellulitis and its treatment on women´s life
- Occurence of adverse events [ Time Frame: 30, 60 and 90 days ]Report and/or observation of side effects,such as discomfort, difficulty to use the stockings or any distress will be registered
- Occurence of venous insufficiency signs [ Time Frame: 30, 60 and 90 days ]Symptoms and signals of venous insufficiency such as fatigue, swelling, burning will be evaluate by a five-point scale:0=none; 1 = slight; 2 = slight to moderate; 3 = moderate to severe; 4 = severe; 5 = unbearable
- Changes in Colour eco-doppler [ Time Frame: 0 and 90 days ]Superficial and deep venous systems will be evaluate before and at the end of the study by colour eco-doppler
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01429428
|Principal Investigator:||Edileia Bagatin, M.D., PhD||Universidade Federal de Sao Paulo, Brasil|